Aminocaproic acid NDC 0904-7165

NDC codes

FDA NDC Directory

Product NDC (as listed)0904-7165Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00904-7165Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0904-7165-07	00904716507	30 BLISTER PACK in 1 CARTON (0904-7165-07) / 1 TABLET in 1 BLISTER PACKMarketed from Nov 30, 2019

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Aminocaproic acid
Generic name (nonproprietary): aminocaproic acid
Active ingredients: Aminocaproic acid — 500 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Major Pharmaceuticals
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 212492
Marketing start: Nov 30, 2019
Listing expires: Dec 31, 2027
Other FDA classes: Decreased Fibrinolysis (Physiologic effect)
Identifiers: Product ID 0904-7165_52582352-b804-4329-bf74-d5297fb778dbSPL ID 52582352-b804-4329-bf74-d5297fb778dbSPL set ID 2612ee97-1723-40f2-99e6-3a736f63200fRxCUI 197351UNII U6F3787206
Pharmacologic class: Antifibrinolytic Agent

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400904716507 followed by a unit qualifier and the quantity

Package 00904-7165-07. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 4, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE Aminocaproic acid tablets are useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life-threatening situations, transfusion of appropriate blood products and other emergency measures may be required. Fibrinolytic bleeding may frequently be associated with surgical complications following heart surgery (with or without cardiac bypass procedures) and portacaval shunt; hematological disorders such as amegakaryocytic thrombocytopenia (accompanying aplastic anemia); acute and life-threatening abruptio placentae; hepatic cirrhosis; and neoplastic disease such as carcinoma of the prostate, lung, stomach, and cervix. Urinary fibrinolysis, usualIy a norma…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 212492

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 212492
Product	Strength	Form · route	Labeler	Product NDC
Aminocaproic acid	Aminocaproic acid 500 mg/1	TabletOral	Amneal Pharmaceuticals LLC	69238-1637